ETR:MDG1 Medigene (MDG1) Stock Price, News & Analysis → Now Open: Crypto emergency update (From InvestorPlace) (Ad) Free MDG1 Stock Alerts €1.92 +0.08 (+4.34%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range€1.82▼€2.0350-Day Range€1.45▼€2.3652-Week Range€1.35▼€2.90Volume21,479 shsAverage Volume306,207 shsMarket Capitalization$47.28 millionP/E RatioN/ADividend Yield1.31%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Medigene alerts: Email Address Ad InvestorPlaceYou’re invited: Biggest crypto event of 2024During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. About Medigene Stock (ETR:MDG1)Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.Read More MDG1 Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDG1 Stock News HeadlinesApril 17, 2024 | finance.yahoo.comMedigene to Present at Upcoming Scientific ConferencesApril 8, 2024 | finance.yahoo.comMedigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024April 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.April 4, 2024 | finanznachrichten.deMedigene: 2024 steht im Zeichen von MDG1015, BioNTech und der FinanzierungApril 4, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG sichert sich europäisches Patent für ihre iM-TCR-TechnologieApril 4, 2024 | finance.yahoo.comMedigene AG Secures European Patent for its iM-TCR TechnologyMarch 28, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG gibt Finanzergebnisse für das Geschäftsjahr 2023 und Unternehmens-Update bekanntMarch 28, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG gibt -2-April 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.March 26, 2024 | finance.yahoo.comWe Think Medigene (ETR:MDG1) Needs To Drive Business Growth CarefullyMarch 19, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG nimmt an der H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference teilMarch 18, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG veröffentlicht Finanzergebnisse für das Geschäftsjahr 2023 am 28. März 2024March 18, 2024 | finance.yahoo.comMedigene AG to report full year 2023 financial results on March 28, 2024March 6, 2024 | finance.yahoo.comMedigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual MeetingMarch 4, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene erweitert Patentportfolio in Japan um iM-TCR-Technologie zur Kontrolle der TCR-T-Sicherheit und -WirksamkeitFebruary 29, 2024 | finanznachrichten.deMedigene AG: Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T TherapiesFebruary 29, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene zeigt auf dem CAR-TCR Summit Europe innovative Ansätze zur Entwicklung differenzierter TCR-T-TherapienFebruary 29, 2024 | markets.businessinsider.comMedigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T TherapiesFebruary 19, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene präsentiert auf folgenden KonferenzenFebruary 19, 2024 | finance.yahoo.comMedigene to Present at Upcoming ConferencesFebruary 12, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene gibt Auswahl der Anwendungsgebiete für die klinische Entwicklung der TCR-T-Therapie bei soliden Tumoren bekanntFebruary 12, 2024 | finanznachrichten.deMedigene AG: Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid TumorsFebruary 12, 2024 | uk.finance.yahoo.comMedigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid TumorsFebruary 12, 2024 | finance.yahoo.comMedigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid TumorsJanuary 2, 2024 | morningstar.comMedigene AG Namen-Akt. nach KapitalherabsetzungDecember 19, 2023 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG nimmt an der 42. Jahrestagung der J.P. Morgan Healthcare Conference teilDecember 19, 2023 | finance.yahoo.comMedigene AG to attend at the 42nd Annual J.P. Morgan Healthcare ConferenceSee More Headlines Receive MDG1 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolETR:MDG1 CUSIPN/A CIKN/A Webwww.medigene.de Phone+49-89-2000330FaxN/AEmployees87Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)(€0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth7.12Net Income$-16,180,000.00 Net Margins-268.10% Pretax MarginN/A Return on Equity-55.69% Return on Assets-24.21% Debt Debt-to-Equity Ratio14.00 Current Ratio2.53 Quick Ratio5.85 Sales & Book Value Annual Sales$6.03 million Price / Sales7.84 Cash Flow€1.41 per share Price / Cash Flow1.37 Book Value€0.86 per share Price / Book2.24Miscellaneous Outstanding Shares24,560,000Free FloatN/AMarket Cap$47.28 million OptionableNot Optionable Beta0.85 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Selwyn Ho MB BS (Age 53)MBBS, CEO & Member of Executive Management Board Comp: $384.47kDr. Dolores J. SchendelChief Scientific Officer, Member of Executive Management Board and Head of Research & DevelopmentDr. Ernst-Ludwig Winnacker (Age 83)Co-Founder & Chairman Scientific Advisory Board Comp: $20kDr. Birger KohlertChief Financial OfficerPamela KeckVice President of Investor Relations & Corporate CommunicationsDr. Kirsty Crame M.D.VP and Head of Clinical Research & DevelopmentMore ExecutivesKey CompetitorsGenfitEPA:GNFTBiotest AktiengesellschaftETR:BIOMorphoSysETR:MOREssilor International Société AnonymeEPA:EIFielmann GroupFRA:FIEView All Competitors MDG1 Stock Analysis - Frequently Asked Questions How have MDG1 shares performed in 2024? Medigene's stock was trading at €1.53 at the start of the year. Since then, MDG1 stock has increased by 26.2% and is now trading at €1.93. View the best growth stocks for 2024 here. What other stocks do shareholders of Medigene own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medigene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP). This page (ETR:MDG1) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchUrgent alert: open this for a huge profit potentialTimothy SykesThe #1 Crypto for 2024InvestorPlaceTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medigene AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.